ArticleNPJ Parkinson's disease2024
Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson's Disease.
Article in NPJ Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Elevated neurofilament light chain (NfL) in blood and CSF as a biomarker for Parkinson's disease cognitive impairment: A meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Potential protein blood-based biomarkers for cognitive dysfunction in Parkinson's disease: a systematic review and network meta-analysis.Frontiers in aging neuroscience · 2026Pooled it
- Human biomarker navigator.iMeta · 2026Review
- What's in a name? reframing advanced Parkinson's disease as a multidimensional state.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach.Trends in molecular medicine · 2026Review
- Disease modification in advanced Parkinson's disease: a review and roadmap for paving the way for next-generation interventions.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Plasma neurofilament light chain in early Parkinson's disease predicts motor complications: a prospective cohort study.NPJ Parkinson's disease · 2026Article
- From Bench to Bedside: Neurofilament Light Chain as a Biomarker in Ischemic Stroke.Current medical science · 2026Review
- Lithium's effects on serum neurofilament light in Parkinson's disease: A post hoc analysis.IBRO neuroscience reports · 2026Article
- A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism.Nature medicine · 2026Article
- A Biological Framework for Parkinson's Disease: Advances in α-Synuclein-Centered Biomarkers and Staging.Journal of neurochemistry · 2026Review
- Serum Neurofilament Light Chain and GFAP Levels Are Associated with Structural Brain Connectivity in Parkinson's Disease.International journal of molecular sciences · 2026Article
- Review
- Bridging global diversity gaps in Parkinson disease research.Nature reviews. Neurology · 2026Review
- Machine learning integration of serial blood biomarkers enhances cognitive decline prediction in early Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Lithium as a disease-modifying therapy for Parkinson's disease: mechanisms, preclinical evidence, and clinical prospects.Clinical parkinsonism & related disorders · 2026Review
- JNK3 quantification in plasma: a novel biomarker for neuronal damage in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Plasma neurofilament light chain as a predictor of multiple system atrophy in idiopathic REM sleep behavior disorder.Journal of neurology · 2025Article
- Article
- Plasma NfL and GFAP in the preclinical stages of neurodegenerative diseases: insights from the UK Biobank.Journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Neurofilament light chain (NFL) is elevated in neurodegenerative diseases, including Parkinson's disease (PD). This study aimed to investigate serum NFL in newly diagnosed PD and its association with cognitive and motor decline over 10 years. Serum NFL levels were measured in PD patients and controls from the ParkWest study at diagnosis (baseline) and after 3 and 5 years. Mixed-effects regression analyzed changes in NFL and the association with annual changes in MMSE and UPDRS-III scores over 10 years. PD patients had elevated serum NFL at all visits and a faster annual increase over 5 years compared to controls (0.09 pg/mL per year; p = 0.029). Higher baseline NFL predicted faster cognitive decline β -0.77 transformed MMSE; p = 0.010), and a 40% NFL increase predicted future motor decline (β 0.28 UPDRS-III; p = 0.004). Elevated serum NFL in early PD is linked to faster cognitive and motor impairment, suggesting its prognostic value in PD biomarker panels.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.